Monday July 16, 2018
Home India Narendra Modi...

Narendra Modi pays Tribute to India’s Former PM Narasimha Rao on his 95th Birth Anniversary

Narasimha Rao was India's 9th Prime Minister and is referred to as the "Father of Indian Economic Reforms"

1
//
566
P.V. Narasimha Rao. Image source: www.thedailybeast.com
Republish
Reprint
  • PV Narsimha Rao was India’s 8th Prime Minister and is referred to as “Father of Indian Economic Reforms”
  • He died at the age of 83 due to heart attack on December 23, 2004
  • Rao was born on June 28, 1921 at Karimnagar in Telangana

Prime Minister of India, Narendra Modi paid respect to former Prime Minister of India- P.V. Narasimha Rao on his 95th birthday on Tuesday, June 28.

Pamulaparti Venkata Narasimha Rao was by profession an Indian Lawyer and a politician who served India as a Prime Minister from (1991–1996). He was India’s 9th Prime Minister and is referred to as the “Father of Indian Economic Reforms”.

Follow NewsGram at Facebook: NewsGram

PM pays tributr to PV Narsimha Rao (Source: Wikimedia Commons)
PM Narendra Modi pays tribute to P.V. Narasimha Rao Image Source: Wikimedia Commons

“Tributes to P.V. Narasimha Rao on his birth anniversary. He led India at a crucial time and his leadership was both notable and vital,” Modi tweeted.

Follow NewsGram at Twitter: @newsgram1

Narasimha Rao was born on June 28, 1921 at Karimnagar in Telangana and served as the Prime Minister of India from June 21, 1991 to May 16, 1996. P.V. Narasimha Rao died at the age of 83 due to heart attack on 23rd December 2004.

(inputs from IANS)

ALSO READ:

 

Click here for reuse options!
Copyright 2016 NewsGram

  • Vrushali Mahajan

    Mr Narasimha Rao was one of India’s greatest Prime Ministers! A man with ambition

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)